Clinical Application of Small Molecule Tyrosine Kinase Inhibitors for Anti-Angiogenesis in Recurrent, Metastatic, or Advanced Gynecological Tumors: Chinese Expert Consensus (2025 Edition)
Abstract：According to the 2022 data on the burden of malignant tumors released by the National Cancer Center, the number of new cases of cervical cancer, endometrial cancer, and ovarian cancer in China were 150,700, 77,700, and 61,100, respectively, with death cases being 55,700, 13,500, and 32,600 [1]. The treatment of gynecological tumors mainly includes surgery, radiotherapy, and chemotherapy, but tumor treatment failure and recurrence have become a bottleneck in improving survival rates in advanced gynecological tumors.
Keywords：gynecological tumorsantiangiogenic drugsTKIexpert consensus
Publication Date：2025-06-02
Online Publishing Date：2025-08-15(First online date of this platform, not the publication date of the document)
Pages：10( 639-648 )